UK Markets closed

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
90.21+0.52 (+0.58%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close89.69
Bid90.00 x 1300
Ask91.03 x 800
Day's range89.49 - 92.28
52-week range30.05 - 189.89
Avg. volume682,942
Market cap2.617B
Beta (5Y monthly)1.51
PE ratio (TTM)5.70
EPS (TTM)15.82
Earnings date06 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est115.33
  • Business Wire

    Fulgent Genetics to Partner with Houston Health Department and Houston-Area Public Schools on Back-to-School COVID-19 Testing Program

    TEMPLE CITY, Calif., September 23, 2021--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will be partnering with the Houston Health Department and Houston-area public schools to provide COVID-19 testing to students during the current school year.

  • Motley Fool

    3 Unstoppable Healthcare Stocks to Buy With Just $1,000

    Jason Hawthorne (Repligen): Repligen might fly under the radar, but it serves an important role in a fast-growing industry. The stock price reinforces that. The company has benefited from the adoption of biologic drugs over traditional small-molecule chemical compounds.

  • Motley Fool

    The 1 Stock I'd Buy Right Now

    There were a lot of companies that jumped to action last year in the fight against the SARS-CoV-2 virus. In that latter category, one company proved it has a business model to succeed long after the pandemic ends -- assuming it ever does. Fulgent Genetics (NASDAQ: FLGT) burst onto the scene when the Food and Drug Administration (FDA) approved its test for detecting COVID-19 in June 2020.